2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
December 2025 in “Cosmoderma” Systemic corticosteroids help manage vitiligo by slowing progression and aiding repigmentation.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
1 citations
,
October 2024 in “QJM” IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.
3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.
24 citations
,
July 2013 in “Oncologist” Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
January 2026 in “Frontiers in Pharmacology” Wedelolactone may help treat inflammation, infections, cancer, bone loss, and organ damage.
November 2024 in “Journal of Investigative Dermatology” 25 citations
,
October 2010 in “Journal of Hepatology” Budesonide alone is less effective than standard treatment for autoimmune hepatitis.
November 2024 in “Rheumatology Advances in Practice” Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
September 2019 in “Rheumatology advances in practice” Diagnosing and treating rapidly worsening lung disease is difficult and requires better guidelines and understanding.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
12 citations
,
December 2021 in “Frontiers in Medicine” Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.
5 citations
,
December 2023 in “Clinical Case Reports” Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
83 citations
,
October 2012 in “International Journal of Oncology” Wedelolactone selectively kills prostate cancer cells without harming normal cells.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
7 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
5 citations
,
November 2023 in “The Journal of Dermatology” Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.